On the 28th, Daewoong Pharmaceutical announced it had signed an agreement with Neurorive to conduct joint research and development for a new drug candidate for depression. Under the agreement, the two companies will be jointly developing ‘NR-0601,’ a multi-target, non-narcotic oral depression treatment.

Neurorive is a bio venture company that researches central nervous diseases including depression and Alzheimer’s. It is studying NR-0601 as the first new drug in its antidepressant pipeline.

NR-0601 is an oral antidepressant that was derived using Neurorive’s drug screening platform that sends electric signals to living brain tissues to check the response of nerve cells.